drugset / Trial / NCT02792114
T-Cell Therapy for Advanced Breast Cancer
Phase 1
Active not recruiting
186 enrolled
Memorial Sloan Kettering Cancer Center
United States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer.
Timeline
- Start
- 2016-06
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesothelin-targeted T cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1.5 g | — |
| Background | Rimiducid | Other / unclassified | — | — |